Edmond de Rothschild Equity Strategies IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file a simplified tender offer on the company’s remaining shares
Dijon, October 19, 2022 at 08:00am CEST – Oncodesign Services (FR0011766229 – ALONC), a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital (the “Control Block “), from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.
ABOUT ONCODESIGN SERVICES
Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in oncology and immuno-inflammation. The company has world-renowned expertise in the preclinical evaluation of proof of concept of new experimental therapies in oncology and immuno-inflammation as well as numerous other skills and expertise in Medicinal Chemistry, Pharmaco-imaging, Molecular Radiotherapy (MRT), pharmacokinetics, bio-analysis and humanized models. Based in Dijon, France, in the heart of the university and hospital cluster and within the Paris-Saclay cluster, Oncodesign Services has 227 employees in France, Canada and the United States.
More information on the website www.oncodesign-services.com.
ABOUT ELYAN PARTNERS
Elyan Partners SAS (“Elyan”) is a financial investment advisor and partner of Edmond de Rothschild Private Equity. Elyan is the exclusive advisor to the ERES funds and advisor to the Privilege funds of the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America, primarily in four themes: the biotech ecosystem, e-commerce, financial services and new consumers.
Edmond de Rothschild Private Equity is the trade name of the Edmond de Rothschild Group’s private equity entities and has over CHF 3.4 billion of assets under management. With an entrepreneurial approach to finance and supported by strong convictions, Edmond de Rothschild Private Equity builds and develops differentiated investment strategies that provide a sustainable response to environmental and social issues. Founded in 1953, the Group had nearly CHF 178 billion in assets under management as of 31 December 2021, 2,500 employees and 29 offices worldwide.
ABOUT ERES IV
ERES IV is a professional fund managed by Edmond de Rothschild Private Equity (France), authorized by the Autorité des Marchés Financiers (“AMF”), advised by Elyan Partners. ERES IV is a fund registered under French law with the AMF, currently being marketed and reserved for professional investors within the meaning of the MiFID Directive. ERES IV may not be authorized for marketing in the reader’s country of residence. Any investment in private equity involves specific risks, including the risk of capital loss, discretionary management and liquidity risk. It is the responsibility of each investor to analyze his risk by reading the fund’s regulatory documents, which are available free of charge on request from the management company.
The mention of certain investments does not constitute a recommendation to buy or sell the securities or shares of the companies presented
Disclaimer
This press release contains certain forward – looking statements and estimates concerning the Company’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the Company’s control. Consequently, the actual results, financial condition, performances and/or achievements of the Company or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and the Company undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.